|
|
| (2 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| '''Strontium-89''' is an isotope of [[strontium]]. Strontium-89 is a [[beta particle]] emitter with a half-life of 50 days.
| | #REDIRECT [[Strontium chloride]] |
| | |
| ==Physiological effects and Medical use==
| |
| Strontium belongs to the same periodic family as [[calcium]] ([[alkaline earth metal]]s), and is metabolised in a similar fashion. <sup>89</sup>Sr, used in the treatment of osseous (bony) metastases preferentially targets metabolically active regions of the bone.<ref name="HalperinPerez2008">{{cite book|last1=Halperin|first1=Edward C.|last2=Perez|first2=Carlos A.|last3=Brady|first3=Luther W.|title=Perez and Brady's principles and practice of radiation oncology|url=http://books.google.com/books?id=NyeE6-aKnSYC&pg=PA1997|accessdate=19 July 2011|year=2008|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-6369-1|pages=1997–}}</ref> As such, intravenous or intracavity administration of <sup>89</sup>Sr may be helpful in the palliation of painful bony metastases, as it allows for targeted radiation to metastatic lesions, inducing apoptosis of cells, membrane and protein damage. Subsequently, bone pain resulting from cytokine release at the site of lesions, bone-associated nerve compression and stretching of the periosteum may be reduced. Treatment with <sup>89</sup>Sr has been particularly effective in patients with hormonally-resistant prostate cancer, often leading to a decreased requirement for narcotic analgesics, an increase in time until further radiation, and a decrease in tumour markers.
| |
| | |
| It is an artificial radioisotope which is used in treatment of [[bone cancer]]. In circumstances where cancer patients have widespread and painful bony metastases, the administration of <sup>89</sup>Sr results in the delivery of [[beta particle]]s directly to the area of bony problem, where calcium turnover is greatest.
| |
| | |
| ==See also==
| |
| * [[Isotopes of strontium]]
| |
| * [[Alpharadin]], Radium-223 with similar clinical use.
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Radiation oncology}}
| |
| {{Therapeutic radiopharmaceuticals}}
| |
| [[Category:Isotopes of strontium|Strontium-089]] | |
| | |
| Mertens, W. C., Filipczak, L. A., Ben-Josef, E., Davis, L. P. and Porter, A. T. (1998), Systemic bone-seeking radionuclides for palliation of painful osseous metastases: Current concepts. CA: A Cancer Journal for Clinicians, 48: 361–374. doi: 10.3322/canjclin.48.6.361
| |
| | |
| {{isotope-stub}}
| |